MedTrace Logo

Intravenous Iron Pre-treatment in Prognathic Surgery

NCT02800746 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-03-20

No results posted yet for this study

Summary

The objective of the present study is to determine the impact of preoperative IV-iron (ferric carboxy maltose) supplementation on postoperative hematocrit values and allogenic blood transfusion amount in patients undergoing elective prognathic surgery.

Conditions

  • Prognathic Surgery

Interventions

DRUG

Ferric carboxymaltose

Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.

DRUG

Placebo

normal saline 100 ml is intravenously administered on 7-10 day before surgery

Sponsors & Collaborators

  • Konkuk University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-30
Primary Completion
2018-12-31
Completion
2018-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02800746 on ClinicalTrials.gov